Iovance Biotherapeutics, Inc. (IOVA) Net Income by Year
Iovance Biotherapeutics, Inc. reported a net loss of $391.0M in fiscal year 2025. This represents a decrease of 5.1% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to a $289.5M net loss. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Iovance Biotherapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
IOVA Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | TTM | FY2510-K | FY2410-K | FY2310-K | FY22DEF 14A | FY21DEF 14A | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$289.5M | -$391.0M-5.1% | -$372.2M+16.2% | -$444.0M-12.1% | -$395.9M-15.7% | -$342.3M-31.9% | -$259.6M-31.4% | -$197.6M-59.9% | -$123.6M-34.2% | -$92.1M-74.1% | -$52.9M-91.2% | -$27.7M-129.8% | -$12.0M+52.6% | -$25.4M | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
IOVA Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Iovance Biotherapeutics, Inc. financials
Frequently Asked Questions
What was Iovance Biotherapeutics, Inc.'s net income in fiscal year 2025?
Iovance Biotherapeutics, Inc. reported a net loss of $391.0M in fiscal year 2025.
How fast is Iovance Biotherapeutics, Inc.'s net income growing?
Iovance Biotherapeutics, Inc. (IOVA) net income fell by 5.1% year over year, from -$372.2M to -$391.0M in fiscal year 2025.
What is Iovance Biotherapeutics, Inc.'s net income over the last twelve months?
Iovance Biotherapeutics, Inc. (IOVA) reported a $289.5M net loss over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
What was Iovance Biotherapeutics, Inc.'s net income in the most recent quarter?
Iovance Biotherapeutics, Inc. (IOVA) reported -$47.3M in net income in Q2 2026. This represents an increase of 57.6% from the same quarter a year earlier.
What does net income mean on a financial statement?
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Iovance Biotherapeutics, Inc. (IOVA) reported on that line in every period on record.